Cadila Healthcare has received USFDA approval for Haloperidol Decanoate injection used in treatment of schizophrenia.
It is also used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome. The drug will be made in strengths of Haloperidol Decanoate injection, 50 mg (base)/mL and 100 mg (base)/mL, single-dose vials, 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL).
The drug will be manufactured at Liva Pharma’s manufacturing facility at Vadodara, Cadila Healthcare.
Company Profile : Cadila Healthcare Ltd